Switch theme
Sign up to access all valuation multiples
China Traditional Chinese Medicine Holdings Co Ltd is engaged in the Chinese healthcare sector. The company functions through four segments: Yi Fang, Tian Jiang, Tong Ji Tang, and Medi-World. It generates maximum revenue from the Yifang segment which mainly engages in the manufacture and sales of concentrated TCM granules (CTCMG), TCM healthcare products, and TCM decoction pieces under the Yi Fang brand. The majority of the revenue of the Yi Fang segment is derived from the sales of CTCMG. Geographically, it derives a majority of its revenue from Mainland China.
1992
17.3K+
LTM Revenue $2.4B
LTM EBITDA $241M
$1.1B
Benchmark forward-looking revenue and EBITDA valuation multiples across generative AI, climate tech, semiconductors, online marketplaces, vertical SaaS and 220 more verticals.
China TCM has a last 12-month revenue of $2.4B and a last 12-month EBITDA of $241M.
In the most recent fiscal year, China TCM achieved revenue of $2.3B and an EBITDA of $329M.
China TCM expects next 12-month revenue of XXX and NTM EBITDA of XXX
See China TCM valuation multiples based on analyst estimates| FY 2023 | FY 2024 | FY 2025 | LTM | NTM | |
|---|---|---|---|---|---|
| Revenue | $1.8B | $2.3B | XXX | XXX | XXX |
| Gross Profit | $1.5B | $926M | XXX | XXX | XXX |
| Gross Margin | 83% | 40% | XXX | XXX | XXX |
| EBITDA | $278M | $329M | XXX | XXX | XXX |
| EBITDA Margin | 15% | 14% | XXX | XXX | XXX |
| Net Profit | $249M | $98.3M | XXX | XXX | XXX |
| Net Margin | 14% | 4% | XXX | XXX | XXX |
| Net Debt | $266M | $244M | XXX | XXX | XXX |
Financial data powered by Morningstar, Inc.
As of April 18, 2025, China TCM's stock price is HKD 2 (or $0).
China TCM has current market cap of HKD 9.8B (or $1.3B), and EV of HKD 8.4B (or $1.1B).
See China TCM trading valuation data| EV | Market Cap | Price 1D | Price 1M | Price 3M | Price 12M | EPS |
|---|---|---|---|---|---|---|
| $1.1B | $1.3B | XXX | XXX | XXX | XXX | $0.01 |
Sign up to access valuation multiples like growth-adjusted P/E, next 12-month EV/Revenue, EBITDA multiples by industry and many more
Sign UpAs of April 18, 2025, China TCM has market cap of $1.3B and EV of $1.1B.
China TCM's trades at 0.5x LTM EV/Revenue multiple, and 4.8x LTM EBITDA.
Analysts estimate China TCM's 2025E EV/Revenue multiple at XXX and 2025E EV/EBITDA multiple at XXX
See valuation multiples for China TCM and 10K+ public comps| FY 2024 | FY 2025E | FY 2026E | FY 2027E | |
|---|---|---|---|---|
| EV | $1.1B | XXX | XXX | XXX |
| EV/Revenue | 0.5x | XXX | XXX | XXX |
| EV/EBITDA | 3.3x | XXX | XXX | XXX |
| P/E | 7.6x | XXX | XXX | XXX |
| P/E/Growth | -1.2x | XXX | XXX | XXX |
| EV/FCF | 12.3x | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Access all public comps and forward-looking valuation multiples like EV/Revenue in 2025, based on equity research analyst estimates.
Sign UpChina TCM's NTM/LTM revenue growth is 1%
China TCM's revenue per employee for the last fiscal year averaged $0.1M, while opex per employee averaged $0.1M for the same period.
Over next 12 months, China TCM's ratio of sales and marketing spend to revenue is estimated to be XXX , while its R&D spend to revenue to be XXX .
Analysts estimate China TCM's 2025E EV/Revenue multiple at XXX and 2025E EV/EBITDA multiple at XXX
See operational valuation multiples for China TCM and other 10K+ public comps| FY 2024 | NTM | FY 2025E | FY 2026E | FY 2027E | |
|---|---|---|---|---|---|
| Revenue Growth | 27% | XXX | XXX | XXX | XXX |
| EBITDA Margin | 14% | XXX | XXX | XXX | XXX |
| EBITDA Growth | 18% | XXX | XXX | XXX | XXX |
| Rule of 40 (SaaS-only) | 15% | XXX | XXX | XXX | XXX |
| Revenue per Employee | $0.1M | XXX | XXX | XXX | XXX |
| Opex per Employee | $0.1M | XXX | XXX | XXX | XXX |
| S&M Expenses to Revenue | 35% | XXX | XXX | XXX | XXX |
| G&A Expenses to Revenue | 6% | XXX | XXX | XXX | XXX |
| R&D Expenses to Revenue | 4% | XXX | XXX | XXX | XXX |
| Opex to Revenue | 44% | XXX | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Benchmark public comps and private revenue and EBITDA valuation multiples across GRC software, cloud infrastructure, DevOps, online marketplaces and so much more!
| EV/Revenue | EV/EBITDA | |||||
|---|---|---|---|---|---|---|
| 2025E | 2026E | 2027E | 2025E | 2026E | 2027E | |
| Julphar | XXX | XXX | XXX | XXX | XXX | XXX |
| Galapagos | XXX | XXX | XXX | XXX | XXX | XXX |
| Pharming | XXX | XXX | XXX | XXX | XXX | XXX |
| Vivoryon Therapeutics | XXX | XXX | XXX | XXX | XXX | XXX |
| Armata Pharmaceuticals | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc.
China TCM acquired XXX companies to date.
Last acquisition by China TCM was XXXXXXXX, XXXXX XXXXX XXXXXX . China TCM acquired XXXXXXXX for XXX (EV/Revenue multiple of XXX ).
See M&A valuation multiples| Acquired Company | EV | EV/Revenue | EV/EBITDA |
|---|---|---|---|
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
Sign up to see revenue and EBITDA valuation multiples for 60K+ M&A deals.
Sign Up| When was China TCM founded? | China TCM was founded in 1992. |
| Where is China TCM headquartered? | China TCM is headquartered in Hong Kong. |
| How many employees does China TCM have? | As of today, China TCM has 17.3K+ employees. |
| Is China TCM publicy listed? | Yes, China TCM is a public company listed on HKG. |
| What is the stock symbol of China TCM? | China TCM trades under 00570 ticker. |
| When did China TCM go public? | China TCM went public in 1993. |
| Who are competitors of China TCM? | Similar companies to China TCM include e.g. Julphar, Galapagos, Pharming, Vivoryon Therapeutics. |
| What is the current market cap of China TCM? | China TCM's current market cap is $1.3B |
| What is the current revenue of China TCM? | China TCM's last 12-month revenue is $2.4B. |
| What is the current EBITDA of China TCM? | China TCM's last 12-month EBITDA is $241M. |
| What is the current EV/Revenue multiple of China TCM? | Current revenue multiple of China TCM is 0.5x. |
| What is the current EV/EBITDA multiple of China TCM? | Current EBITDA multiple of China TCM is 4.8x. |
| What is the current revenue growth of China TCM? | China TCM revenue growth between 2023 and 2024 was 27%. |
| Is China TCM profitable? | Yes, China TCM is EBITDA-positive (as of the last 12 months). |
Get access to always up-to-date, precisely categorized 70K+ public and private valuation multiples, across tech and beyond.
